about
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpressionInhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease modelsSelective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's diseaseIn vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cellsWnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathwayGlucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neuronsEmbryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat modelReducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protectionProteasome activator enhances survival of Huntington's disease neuronal model cellsGlobal gene expression profiling of somatic motor neuron populations with different vulnerability identify molecules and pathways of degeneration and protectionCellular and molecular treatments of neurological diseases.Integrated molecular landscape of Parkinson's diseaseGene therapy in the CNS.High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neuronsLong-term health of dopaminergic neuron transplants in Parkinson's disease patients.The transcription factor orthodenticle homeobox 2 influences axonal projections and vulnerability of midbrain dopaminergic neurons.Impact of genomics on drug discovery and clinical medicine.Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid.Immature and neurally differentiated mouse embryonic stem cells do not express a functional Fas/Fas ligand system.Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeuticsImproved surgical cell therapy in Parkinson's disease. Physiological basis and new transplantation methodology.Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.Models of repair mechanisms for future treatment modalities of Parkinson's disease.Cell therapy and stem cells in animal models of motor neuron disorders.Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration.Functional imaging of the dopamine system: in vivo evaluation of dopamine deficiency and restoration.Regulation of dopamine cell type and transmitter function in fetal and stem cell transplantation for Parkinson's disease.Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients.Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells.A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat.Progressive decline of glucocerebrosidase in aging and Parkinson's disease.Sorting the wheat from the chaff in dopamine neuron-based cell therapies.Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease.Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activationSustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
P50
Q22001521-B6955D41-6BA5-4A65-BABF-CD8E06CF56D2Q24673667-2A452A80-128B-49E2-B56A-F4573BD08A59Q24794457-B16D7A3C-C207-4535-A655-07E29BC6192EQ26774092-2ADBAD07-59B1-44CF-B892-3BCBDF7B602BQ28118756-5AFA8177-930E-4E78-B353-AAA01A0EAC43Q28118869-13A714DB-9B38-4359-BB75-127AE3A8BC51Q28344741-63C1C924-C272-4CDD-9BFC-0136D141272BQ30833707-AF349FC2-80CA-432D-B834-33485C4BD637Q31172552-86EA33D3-AE56-418F-BF0A-DE7A0A23C6A5Q33275949-F05A0395-CDC5-487C-903E-4CBA639BB39CQ33687971-8E7B57CD-100D-4179-A9AB-27DCBE85D19EQ33732488-DE7B2AF0-BC85-49CC-AF08-7FCBB0FDB93CQ33767544-F4CF7F33-A859-42EB-9A1E-4CAB2E01B22EQ33837123-D9344564-B1E7-4DAC-8349-1453980DC956Q33919434-C5C4636D-42BE-42B2-A053-C397EF775744Q33927216-510D73CD-4FE5-4C1E-B4A3-E45F1669CE4FQ33928831-C1CCE323-CC4D-42AD-832A-560A8176F49EQ33944226-CF63E215-D5A4-41F3-A3A7-B416B682FAA5Q33954700-4D8D6757-D37E-48E4-9121-A72F82CF745DQ34156273-484A3D82-7BB9-4C6B-8678-3AA59BC2FB16Q34182377-E7A5673B-4422-492E-B876-4A18C3FA3212Q34197111-619E88DD-6B66-47F4-8F7C-E26B06B35FD6Q34366970-1016FD07-BF9A-48F5-B800-013D0641DE40Q34416128-749B5BCD-EA64-4158-8293-7F4B46A73E4AQ34657654-991ADD0A-63BB-42AD-ABBB-7439CA3659EFQ34693599-3E4D0ED8-CBBE-48E5-9D83-7E6FB4106464Q34769948-19B9E800-CAB4-4E0A-A25A-B3F6A7212140Q34786812-F8841C5D-15A0-4391-B0F4-71CA3E970D55Q34995006-032EB9C8-C427-4047-A450-E7CC4C78AD86Q34997798-5C4F817B-A77A-4CEE-ADD3-680F12077677Q34999790-66C28E68-25CC-4D68-80B2-AD5018CE8798Q35094909-1CCF36EB-2B6B-48CC-9148-879FD4D7CE31Q35224798-79218974-353D-481E-AF66-6C270F37EA6AQ35374311-67CEFDBF-E0B9-4EC8-98AD-F939FD152570Q35469684-5C0BA241-9077-4478-866A-8E4D780EE81EQ35485792-BF5D8C7A-5928-4B63-96F0-1C62CF7B08F8Q35526468-5326BD4D-4A6F-4CF1-AA1D-8C8CB9844259Q35711351-C175F321-F015-43DE-B58E-E4ADF09C3FBDQ35734048-33055A2A-4872-4366-8CA8-36FAD8A67CA7Q35982198-729CE501-B6B0-4827-856B-DF7118F254F4
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
Ole Isacson
@ast
Ole Isacson
@en
Ole Isacson
@es
Ole Isacson
@nl
type
label
Ole Isacson
@ast
Ole Isacson
@en
Ole Isacson
@es
Ole Isacson
@nl
altLabel
Isacson O
@en
O Isacson
@en
prefLabel
Ole Isacson
@ast
Ole Isacson
@en
Ole Isacson
@es
Ole Isacson
@nl
P1006
P214
P1006
P106
P214
P31
P4012
P496
0000-0001-8091-8302
P7859
viaf-281641282